EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, OMER: Omeros Corp

09 Jan 26 15:59
LAST:

12.49

CHANGE:
 0.96		OPEN:
13.78		HIGH:
14.25		ASK:
18.65		VOLUME:
3.77M
CHG(%):
7.14		PREV:
13.45		LOW:
12.45		BID:
13.10		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
09 Jan 2613.6614.2512.4512.494.59M
08 Jan 2614.5216.1413.4113.454.97M
07 Jan 2613.6114.6113.6014.094.29M
06 Jan 2615.0915.1313.5113.535.32M
05 Jan 2616.3716.3915.2915.403.0M
02 Jan 2617.5017.6316.2916.382.84M
31 Dec 2516.6817.3516.1317.182.81M
30 Dec 2516.5717.4716.0016.964.26M
29 Dec 2515.1716.6414.4316.575.56M
26 Dec 2515.3515.8714.2115.717.16M

PROFILE

Name:Omeros Corp
About:Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Sector:Healthcare
Industry:Biotechnology
Address:The Omeros Building, Seattle, WA, United States, 98119
Website:https://www.omeros.com
CUSIP:682143102
CIK:0001285819
ISIN:US6821431029
FIGI:BBG000JLP4B4
LEI:549300CJWLXX2MXVVV71

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-2.66 
Forward P/E:375.73 
PEG Ratio:0.05 
Price to Sales:4.93 
Price to Book:-4.48 
Return on Assets:-0.31 
Return on Equity:0.86 
EPS Ratio:-2.11 
Revenue:-30,004,000 
Shares:70.9M 
Market Cap:885.55M 

TECHNICAL INDICATORS

MA5:13.7910.4%
MA10:15.1821.5%
MA20:12.580.7%
MA50:10.2022.5%
MA100:7.6463.6%
MA200:6.11104.4%
STO14:42.02
RSI14:60.73 
WPR14:-55.61
MTM14:2.89
ROC14:0.30 
ATR:2.00 
Week High:17.6341.2%
Week Low:12.450.3%
Month High:17.6541.3%
Month Low:8.27104.4%
Year High:17.6541.3%
Year Low:2.95323.4%
Volatility:64.38